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Edited by Hans-Dieter KlenkAbstract Severe acute respiratory syndrome (SARS) is charac-
terized by rapidly progressing respiratory failure resembling
acute/adult respiratory distress syndrome (ARDS) associated
with uncontrolled inﬂammatory responses. Here, we demon-
strated that, among ﬁve accessory proteins of SARS coronavirus
(SARS-CoV) tested, 3a/X1 and 7a/X4 were capable of activating
nuclear factor kappa B (NF-jB) and c-Jun N-terminal kinase
(JNK), and signiﬁcantly enhanced interleukin 8 (IL-8) promoter
activity. Furthermore, 3a/X1 and 7a/X4 expression in A549 cells
enhanced production of inﬂammatory chemokines that were
known to be up-regulated in SARS-CoV infection. Our results
suggest potential involvement of 3a/X1 and 7a/X4 proteins in
the pathological inﬂammatory responses in SARS.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Severe acute respiratory syndrome (SARS) is characterized
by dyspnea with rapidly progressing changes on radiography
in the later stages of the illness [1,2]. Pathological ﬁndings of
the lungs in SARS resemble those in acute/adult respiratory
distress syndrome (ARDS) associated with various clinical
conditions [3]. It has been proposed that ARDS is the outcome
of an uncontrolled inﬂammatory response and that nuclearAbbreviations: ARDS, acute/adult respiratory distress syndrome;
EGFP, enhanced green ﬂuorescent protein; ELISA, enzyme-linked
immunosorbent assay; HA, hemagglutinin; IL-8, interleukin 8; JNK,
Jun N-terminal kinase; NF-jB, nuclear factor kappa B; ORF, open
reading frame; RANTES, regulated on activation normal T cell exp-
ressed and secreted; SARS-CoV, severe acute respiratory syndrome
coronavirus
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doi:10.1016/j.febslet.2006.11.046factor kappa B (NF-jB) is a critical transcription factor in-
volved in the pathogenesis of ARDS [4,5].
SARS coronavirus (SARS-CoV) genome contains open
reading frames (ORFs) for several accessory proteins without
sequence similarity to known coronavirus proteins. These in-
clude 3a (originally called X1 or ORF3), 3b (X2 or ORF4), 6
(X3 or ORF7), 7a (X4 or ORF8), and 8b (X5 or ORF11) [6–
8]. Here, we investigated whether these accessory gene products
of SARS-CoV were able to induce inﬂammatory responses.2. Materials and methods
2.1. Construction of lentivirus vectors expressing SARS-CoV proteins
DNA fragments corresponding to the SARS-CoV 3a/X1, 3b/X2, 6/
X3, 7a/X4, and 8b/X5 genes (identical to the Urbani strain, GenBank
accession number AY278741) were ampliﬁed by polymerase chain
reaction (PCR) from cDNA from the Hanoi 01-03 strain [9] of
SARS–CoV using the speciﬁc primers 5 0-CACCATGGATTTGTT-
TATGAGA-30 (forward) and 5 0-CAAAGGCACGCTAG-
TAGTCGTCG (reverse) for 3a/X1; 5 0-CACCATGATGCCAACTA-
CTTTGTTTGC-3 0 (forward) and 5 0-ACGTACCTGTTTCTTCC-
GAAACG-30 (reverse) for 3b/X2; 5 0-CACCATGTTTCATCTT-
GTTGACTTCC-3 0 (forward) and 5 0-TGGATAATCTAACTCCAT-
AGGTTC-3 0 (reverse) for 6/X3; 5 0-CACCATGAAAATTATTCT-
CTTCCTG-3 0 (forward) and 5 0-TTCTGTCTTTCTCTTAATGGT-
GAAGC-30 (reverse) for 7a/X4; 5 0-CACCATGTGCTTGAAGAT-
CCTTGTAAG-3 0 (forward) and 5 0-ATTTGTTCGTTTATTTAAA-
ACAACAAG-3 0 (reverse) for 8b/X5. Each ampliﬁed fragment was in-
serted into the pENTR/D-TOPO vector (Invitrogen, Carlsbad, CA),
and was subsequently transferred into a modiﬁed lentivirus expression
vector (pLenti6/V5-DEST, Invitrogen) containing an intron of human
beta-globin (Fig. 1A) by site-speciﬁc recombination using the Gateway
Cloning System (Invitrogen). They were designated as pLenti/V5/X1,
pLenti/V5/X2, pLenti/V5/X3, pLenti/V5/X4, and pLenti/V5/X5,
respectively. An enhanced green ﬂuorescent protein (EGFP)-express-
ing vector (pLenti/V5/GFP) was also constructed as a control.2.2. Plasmids
A reporter plasmid expressing luciferase (jB-Luc) driven by ﬁve tan-
dem NF-jB binding sites derived from IL-2 receptor a [10] was pro-
vided by Dr. Junichi Fujisawa (Kansai Medical School, Osaka,
Japan). Reporter plasmids for the wild-type (-133-Luc) and various
mutant (AP-1-Luc, NF-jB-Luc, and NF-IL6-Luc) interleukin 8 (IL-
8) promoters [11] were provided by Dr. Naofumi Mukaida (Kanazawa
University, Kanazawa, Japan). The HA-tagged expression vectorsblished by Elsevier B.V. All rights reserved.
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Fig. 1. Expression of SARS-CoV accessory proteins. (A) Locations of SARS-CoV 3a/X1 (X1), 3b/X2 (X2), 6/X3 (X3), 7a/X4 (X4), and 8b/X5 (X5)
gene fragment ampliﬁed (gray squares) (top) and the construct of the resulting lentivirus vectors expressing SARS-CoV genes (pLenti/V5/X1-X5)
(bottom) are schematically shown. (B) Western blot analysis of cell lysates from HEK293T cells transfected with the indicated SARS-CoV gene
expression plasmid (pLenti/V5/X1-X5) was carried out using an anti-V5 antibody. Arrows indicate predicted sizes of each product.
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Fig. 2. Activation of NF-jB by SARS-CoV accessory gene expression.
(A) The NF-jB reporter plasmid (jB-Luc) (closed bar) and phRL-
CMV (open bar) were cotransfected with pLenti/V5/X1-X5 or control
pLenti/V5/GFPvectors (X1-5, C) into HEK293T cells, and luciferase
activities were measured approximately 40 h after transfection. Data
were expressed as means ± S.D. (n = 3) of the relative values against
GFP controls. Similar results were obtained in three independent
experiments. *P < 0.05 vs GFP controls.
6808 N. Kanzawa et al. / FEBS Letters 580 (2006) 6807–6812HA-JNK1 and HA-JNK3 were provided by Dr. Hidenori Ichijo (The
University of Tokyo, Tokyo, Japan). A control plasmid expressing re-
nilla luciferase driven by the cytomegalovirus promoter (phRL-CMV)
was purchased from Promega (Madison, WI).
2.3. Western blotting
Cell lysates were prepared in lysis buﬀer (20 mM Tris–Hcl [pH 7.5],
150 mM NaCl, 10% glycerol, 1% Triton X-100 and protease inhibitor
cocktail [CALBIOCHEM, La Jolla, CA]), and proteins (20 lg) were
separated by electrophoresis on a Tris–Glycine minigel (Invitrogen),
transferred to nitrocellulose ﬁlters, and reacted with antibodies fol-
lowed by visualization with the enhanced chemiluminescence (ECL)
system (Amersham Pharmacia Biotech, Piscataway, NJ). Densitome-
toric analysis was performed on scanned ﬁlters using ImageJ 1.37v
software (http://rsb.info.nih.gov/ij/).
2.4. Antibodies
Anti-V5 antibody (Invitrogen) and anti-phospho Jun N-terminal ki-
nase (JNK) antibody (Cell Signaling Technology, Beverly, MA) were
used for Western blotting. Immunoprecipitation was performed with
anti-HA (Roche) or anti-V5 antibodies as previously described [12].
2.5. Reporter assays
Luciferase-expressing various reporter plasmids (200 or 300 ng) to-
gether with renilla luciferase-expressing phRL-CMV (20 ng) were co-
N. Kanzawa et al. / FEBS Letters 580 (2006) 6807–6812 6809transfected with vectors expressing SARS-CoV genes into HEK293T
or A549 cells (2 · 105 cells) using Lipofectamine2000 (Invitrogen) or
Fugene6 (Roche), respectively. Luciferase and renilla luciferase activi-
ties were measured from cell lysates 30 or 40 h after transfection, using
the Luciferase assay system (Promega) and the Renilla luciferase assay
system (Promega), respectively.
2.6. Enzyme-linked immunosorbent assay (ELISA)
The amounts of IL-8 and regulated on activation normal T cell ex-
pressed and secreted (RANTES) in the culture supernatants of A549
cells were measured by Quantikine human IL-8 and RANTES ELISA
kits (R&D Systems), respectively, 48 h after transfection.3. Results and discussion
3.1. Expression of SARS-CoV accessory proteins
Lentivirus expression vectors for SARS-CoV 3a/X1, 3b/X2,
6/X3, 7a/X4, and 8b/X5 genes were constructed as shown in
Fig. 1A. These expression vectors were transfected intoPhospho-JNK1
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Fig. 3. Activation of JNK by SARS-CoV accessory gene expression.
(A) Lysates from HEK293T cells co-transfected with HA-JNK1
plasmid (3 lg) and pLenti/V5/X1- X5 or control pLenti/V5/GFP
plasmid (X1-5, C) (3 lg) were immunoprecipitated (IP) with mouse
anti-HA antibody and subjected to Western blot (WB) analysis with
rabbit anti-phospho JNK antibody. The ﬁlter was stripped and re-
stained with anti-HA antibody. (B) A similar phosphorylation assay of
HA-JNK1 with diﬀerent doses of pLenti/V5/X1, X4, or X5 (3 or 1 lg)
plasmids. pCDNA3.1 (Invitrogen) plasmid was used to standardize
transfection eﬃciency. (C) A phosphorylation assay on HEK293T cells
that were co-transfected with HA-JNK3 plasmid (3 lg) and the
indicated lentivirus vectors (3 lg). The values at the bottom end of
each lane represent relative densities against control bands.HEK293T cells, and expression of coding proteins with pre-
dicted sizes were conﬁrmed by Western blotting (Fig. 1B). The
expression level of 3b/X2 protein was always lower than the
other SARS-CoV proteins tested in this system. Anti-V5 anti-
body detected two bands of 3a/X1 protein presumably due to
a posttranslational modiﬁcation as recently reported [13].3.2. Activation of NF-jB and JNK by SARS-CoV accessory
proteins
We ﬁrst examined eﬀects of SARS-CoV genes on NF-jB,
the major transcription factors activated in ARDS [5], using
a reporter plasmid expressing luciferase (jB-Luc) [10]. As
shown in Fig. 2, expression of 3a/X1 and 7a/X4 signiﬁcantly
enhanced NF-jB mediated transcription (9.1 and 3.5-folds,
respectively) in HEK293T cells (P < 0.05). The eﬀects of 3b/
X2, 6/X3 and 8b/X5 were not signiﬁcant compared to the
GFP control. We also determined the eﬀect of SARS-CoV
genes on mitogen-activated protein kinases that are also0
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Fig. 4. SARS-CoV 3a/X1 and 7a/X4 augment IL-8 promoter activity
in HEK293T cells. (A) The IL-8 promoter reporter plasmid (closed
bar) and phRL-CMV (open bar) was co-transfected with pLenti/V5/
X1-X5 or control pLenti/V5/GFP plasmid (X1-5, C) into HEK293T
cells, and luciferase activities were measured. *P < 0.05 vs GFP
controls. (B) The wild-type (WT) or mutant (DNF-jB, DAP-1, and
DNF-IL6) IL- 8 promoter reporter plasmids (closed bar) together with
phRL-CMV (open bar) were cotransfected with control or pLenti/V5/
X1 plasmids (C, X1 or X4) into HEK293T cells. Luciferase activities
were measured approximately 40 h after transfection. Data were
expressed as means ± S.D. (n = 3) of the relative values against GFP
controls.
6810 N. Kanzawa et al. / FEBS Letters 580 (2006) 6807–6812associated with chemokine production [14,15]. HA-tagged
JNK1 expressed in HEK293T cells was markedly phosphory-
lated by 3a/X1and 7a/X4 but not by 3b/X2, 6/X3, or 8b/X5
(Fig. 3A and B). 3a/X1 and 7a/X4 also activated JNK3
(Fig. 3C). There was no obvious activation of ERK and
p38a by any SARS-CoV genes tested (data not shown).IP: anti-V5
 WB: anti-V5
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Fig. 5. Eﬀects of SARS-CoV accessory gene expression on IL-8 promoter
transfected with the indicated SARS-CoV gene expression plasmids (pLenti/V
then subjected to Western blot (WB) analysis using the same antibody
immunoglobulin heavy and light chains, respectively. (B) The wild-type IL-
were cotransfected with pLenti/V5/X1-X5 or control plasmids (X1-5, C) into
(WT) or mutant (DNF-jB, DAP-1, and DNF-IL6) IL-8 promoter reporter pla
control or pLenti/V5/X4 plasmids (C, X4) into A549 cells, and luciferase ac
(open bar) were co-transfected with pLenti/V5/X1-X5 or control plasmi
approximately 40 h (B, C) and 30 h (D) after transfection. Data were expr
controls. *P < 0.05 vs GFP controls.3.3. Augmentation of IL-8 promoter activity by SARS-CoV
accessory proteins
We next examined whether SARS-CoV proteins were capa-
ble of activating the promoter of IL-8 that is a representative
chemokine involved in ARDS [16] and regulated by NF-jB
and MAP kinases including JNK [17]. It has been shown thatX1 X2 X3 X4 X5 C
*
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*
ΔΔ Δκ
and NF-jB activities in A549 cells. (A) Cell lysates from A549 cells
5/X1-X5) were immunoprecipitated (IP) with an anti-V5 antibody and
. Arrows indicate predicted sizes of each product. IgH and IgL,
8 promoter reporter plasmid (closed bar) and phRL-CMV (open bar)
A549 cells, and luciferase activities were measured. (C) The wild-type
smids (closed bar) and phRL-CMV (open bar) were co-transfected with
tivities were measured. (D) The jB-Luc (closed bar) and phRL-CMV
ds (X1-5, C) into A549 cells. Luciferase activities were measured
essed as the means ± S.D. (n = 3) of the relative values against GFP
N. Kanzawa et al. / FEBS Letters 580 (2006) 6807–6812 6811the IL-8 level is elevated in the plasma of SARS patients [18].
When the reporter plasmids expressing luciferase under the
control of the human wild-type IL-8 promoter (-133-Luc)
[11] were co-transfected in HEK293T cells, IL-8 promoter
activity was enormously augmented by expression of 3a/X1
(28.7-fold) and 7a/X4 (13.2-fold). The eﬀects of 3b/X2, 6/X3,
and 8b/X5 were not signiﬁcant (Fig. 4A). Augmentation of
the IL-8 promoter activity by 3a/X1 and 7a/X4 was abolished
by a mutation at the NF-jB site in the IL-8 promoter, indicating
that this eﬀect was mainly mediated through NF-jB (Fig. 4B).
3.4. Eﬀects of SARS-CoV accessory proteins in A549 cells
We next examined the eﬀect of SARS-CoV gene products in
human lung cancer-derived A549 cells [19]. The expression lev-
els of SARS-CoV proteins in transiently transfected A549 cells
were lower than those in HEK293T cells, but were detectable
following immunoprecipitation with anti-V5 antibody
(Fig. 5A). In a reporter assay using A549 cells, 7a/X4 showed
the greatest eﬀect on the IL-8 promoter activity (11.2-fold)
among tested (Fig. 5B). Although 3a/X1 showed a 2.2-fold in-
crease in IL-8 promoter activity at an early time point, such as
24 h after transfection (data not shown), it was no longer sig-
niﬁcant 40 h after transfection in A549 cells. A mutation at the
NF-jB site aﬀected 7a/X4-mediated activation of the IL-8 pro-
moter (Fig. 5C), indicating that the eﬀect of 7a/X4 in A549
cells was also mainly mediated through the NF-jB site. A
reporter assay using the jB-Luc plasmid showed that 7a/X4
enhanced NF-jB activity 9.3-fold while 3a/X1 enhanced it
2.8-fold in A549 cells (Fig. 5D).
Thus, 3a/X1 and 7a/X4 were capable of activating NF-jB
and IL-8 promoter, but such eﬀects were predominantly elic-
ited by 3a/X1 in HEK293T cells and by 7a/X4 in A549 cells.
3.5. Enhancement of inﬂammatory chemokine production by
SARS-CoV 3a/X1, and 7a/X4
Finally, we examined whether 3a/X1, and 7a/X4 actually in-
duced inﬂammatory chemokine production in A549 cells. As
shown in Table 1, although A549 cells spontaneously pro-
duced IL-8, expression of 7a/X4 further increased the levels
of IL-8 production. 3a/X1 also enhanced IL-8 production,
but its statistical signiﬁcance was variable (Table 1). Produc-
tion of another chemokine RANTES, that is controlled at least
by NF-jB [20] and up-regulated in SARS-CoV-infected cells
[21], was signiﬁcantly induced by 3a/X1 and 7a/X4 (Table 1).Table 1
Enhancement of IL-8 and RANTES production by SARS-CoV 3a/X1
and 7a/X4
Chemokines Experiment Chemokine production (pg/ml) in
A549 cells expressing
GFP
(control)
3a/X1 7a/X4
IL-8 Exp. 1 685 ± 9 N.D. 1027 ± 111*
Exp. 2 591 ± 16 615 ± 13 719 ± 20*
Exp. 3 1345 ± 56 1767 ± 263 1976 ± 324*
Exp. 4 537 ± 50 708 ± 29* 673 ± 61*
Exp. 5 481 ± 35 641 ± 38* 616 ± 44*
RANTES Exp. 1 101 ± 5 N.D. 442 ± 57*
Exp. 2 80 ± 18 192 ± 11* 362 ± 15*
Exp. 3 12 ± 6 120 ± 35* 175 ± 54*
ND, not determined.
*P < 0.05 vs GFP controls.Both 3a/X1 and 7a/X4 proteins are expressed in SARS-CoV-
infected cells [22]. 3a/X1 protein is a cell membrane-associated
protein, potentially secreted and incorporated into the virion
[23–25]. 7a/X4 protein is located in the cytoplasm [26]. Recent
studies reported that over-expression of 3a/X1 and 7a/X4
induced apoptosis of the cell [27,28]. Our results indicated that
these cell-associated SARS-CoV accessory gene products
could activate NF-jB and JNK, and might be strong
candidates to induce pathological inﬂammatory responses in
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